OUTPATIENT REGISTRY OF CARDIOVASCULAR DISEASES (RECVASA): PROSPECTIVE FOLLOW-UP DATA, ESTIMATION OF RISKS AND OUTCOMES IN PATIENTS WITH ATRIAL FIBRILLATION

Aim. To evaluate outcomes and risk of their occurrence in patients with atrial fibrillation (AF) within 12 months of follow-up in actual outpatient practice.

Material and methods. A total of 3690 patients with AF, arterial hypertension (HT), ischemic heart disease (IHD) and chronic heart failure (CHF) consulted by general practitioners and cardiologists of three outpatient clinics of Ryazan, were enrolled into the outpatient REgistry of CardioVAScular diseAses (RECVASA). 530 of 3690 (14.4%) patients had the diagnosis of "atrial fibrillation" in their outpatient charts. Estimation of the end points within 12 months after inclusion into the registry was performed based on the data received from the contacts with patients or a documented fact of death.

Results. 39 (7.4%) patients had died during this period [30 (76.9%) of them due to cardiovascular causes], 18 (3.4%) – had undergone stroke, 3 (0.6%) – myocardial infarction, 2 (0.4%) patients had cardiovascular surgery. There were 63 hospitalizations due to cardiovascular diseases (CVD). AF did not lead to significant increase in cardiovascular death risk [odds ratio (OR)=1.31, p=0.21] and stroke risk (OR=1.64, р=0.09) within 12 months after inclusion into the registry, but the risk of hospitalization due to CVD was significantly higher(OR=2.88, р=0.0001). Permanent AF significantly increased the risk of stroke (OR=2.07, р=0.04). Such factors as diabetes, prior stroke, systolic blood pressure (SBP)<110 mm Hg and heart rate (HR)≥90 bpm significantly increased all-cause death risk (OR=2.49, р=0.008; OR=2.46, р=0.01; OR=7.6, р=0.003; OR=15.3, р=0.01, respectively). Patients treated with ACE inhibitors or angiotensin receptor blockers (ARB) had lower all-cause and cardiovascular death risks: OR=0.38, р=0.01 and OR=0.25, р=0.02, respectively. Other drugs revealed no significant influence on prognosis.

Conclusion. According to the outpatient registry RECVASA data such factors as permanent type of AF, diabetes mellitus, prior stroke, SBP<110 mm Hg and HR≥90 bpm, ACE inhibitors/ARB prescription significantly influenced prognosis in patients with AF. Estimating outcomes in AF patients, combination with HT, IHD, CHF and non-cardiac comorbidities must be taken into account as well as peculiarities of these diseases drug treatment.

1. Go AS; Mozaffarian D; Roger VL; et al. Heart Disease and Stroke Statistics -2013 Update: A Report From the American Heart Association. Circulation 2013;127: e6-e245.

2. Perk J.; de Backer B.G.; Gohlke H.; et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J 2012;33: 1635-701.

3. WHO Global InfoBase. Available at: https://apps.who.int/infobase/Mortality.aspx. Accessed by 13.08.2014.

4. Health and demographic indicators of the Russian Federation (2012). Statistical materials. Moscow: Russian Ministry of Health; 2013. Russian (Медико-демографические показатели Российской Фе-дерации (2012). Статистические материалы. М.: Минздрав России; 2013).

5. Camm AJ; Kirchof P; Gregory YH; et al. Guidelines for the management of atrial fibrillation. The task force of the management of patient with atrial fibrillation (2010 Version) of the European Society of Cardiology (ESC). Eur Heart J 2010; 31; 2369-429.

6. Diagnosis and treatment of atrial fibrillation. 2012 RSC/RSSA/RACVS guideline. Available at: http://scardio.ru/content/Guidelines/FP_rkj_13.pdf. Accessed by 06.08.2014. Russian (Диагно-стика и лечение фибрилляции предсердий. Рекомендации ВНОК; ВНОА; АССХ (2012). Доступно на: http://scardio.ru/content/Guidelines/FP_rkj_13.pdf. Проверено 06.08.2014).

7. January CT; Wann LS; Alpert JS; et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2014;129: published online March 28; 2014.

8. Wolf PA; Abbott RD; Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-8.

9. Benjamin EJ; Wolf PA; D’Agostino RB; et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98: 946-52.

10. Kannel WB; Wolf PA; Benjamin EJ; Levy D.. Prevalence; incidence; prognosis; and predisposing conditions for AF: population based estimates. Am J Cardiol 1998; 82: 2-9.

11. Hart RG; Pearce LA; Rothbart RM; et al. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 2000; 35: 183-7.

12. Heeringa J; van der Kuip DA; Hofman A; et al. Prevalence; incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27: 949-53.

13. Gliklich RE. Registries for Evaluating Patient Outcomes: A User’s Guide. Rockville; MD: Agency for Healthcare Research and Quality; 2010.

14. Boytsov SA; Martsevich SYu; Kutishenko NP; et al. Registers in cardiology. Basic rules of conduct and a real opportunity. Cardiovascular Therapy and Prevention 2013; 12 (1); 4-9. Russian (Бойцов С.А.; Марцевич С.Ю.; Кутишенко Н.П. и др. Регистры в кардиологии. Основные правила проведе-ния и реальные возможности. Кардиоваскулярная Терапия и Профилактика 2013; 12 (1); 4-9).

15. Boytsov SA; Jakushin SS; Martsevich SYu; et al. Outpatient polyclinic case of cardiovascular diseases in the Ryazan region (REKVAZA): key challenges; the experience of creating and first results. Ration Pharmacother Cardiol 2013; 9 (1): 4-14. Russian (Бойцов С.А.; Якушин С.С.; Марцевич С.Ю. и др. Амбулаторно-поликлинический регистр кардиоваскулярных заболеваний в Рязанской обла-сти (РЕКВАЗА): основные задачи; опыт создания и первые результаты. Рациональная Фарма-котерапия в Кардиологии 2013; 9(1): 4-14).

16. Kerr CR; Humphries KH; Talajic M; et al. The Canadian registry of atrial fibrillation: a noninterventional follow-up of patients after the first diagnosis of atrial fibrillation. Am J Cardiol 1998;82(7-1): 82N-5N.

17. Nieuwlaat R; Capucci A; Camm AJ; et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey in atrial fibrillation. Eur Heart J 2005;26(22):2422-34.

18. Friberg I; Hammar N; Petersson H; Rosenquist M. Increased mortality in paroxysmal atrial fibrillation; report from the Stokholm cohort-study of atrial fibrillation (SCAF). Eur Heart J 2007; 28:2346-83.

19. Camm AJ; Breithardt G; Crijns H; et al. Real-life observations of clinical outcomes with rhythm- and rate-control therapies for atrial fibrillation RECORDAF (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation). J Am Coll Cardiol 2011; 58(5):493-501.

20. Kakkar AK; Mueller I; Bassand JP; et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J 2012; 163(1): 13-19.e1.

21. Christiansen CB; Olesen JB; Gislason G; et al. Cardiovascular and non-cardiovascular hospital admissions associated with atrial fibrillation: a Danish nationwide; retrospective cohort study BMJ Open 2013;3:e001800. doi:10.1136/bmjopen-2012-001800.

22. Potpara T; Polovina M.M.; Mujovic N.M. Patient preferences at ten years following initial diagnosis of atrial fibrillation: the Belgrade Atrial Fibrillation Study. Patient Preference and Adherence 2013:7 835-42.

23. Andersson T; Magnusson A; Bryngelsson IL; et al. All-cause mortality in 272186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term case control study. Eur Heart J 2013; 34; 1061-7.

24. Oldgren J; Healey JS; Ezekowitz M; et al. Variations in etiology and management of atrial fibrillation in a prospective registry of 15;400 emergency department patients in 46 countries: The RE-LY AF Registry. Circulation 2014; doi:10.1161/circulationaha.113.005451.

25. Loukianov MM; Boytsov SA; Yakushin SS; et al. Diagnostics; treatment; associated cardiovascular and concomitant non-cardiac diseases in patients with diagnosis "atrial fibrillation" in real outpatient practice (according to data of REgistry of CardioVAScular diseAses; RECVASA). Ration Pharmacother Cardiol 2014; 10 (4): 366-77. Russian (Лукьянов М.М.; Бойцов С.А.; Якушин C.С. и др. Диагностика; лечение; сочетанная сердечно-сосудистая патология и сопутствующие заболевания у больных с диагнозом «фибрилляция предсердий» в условиях реальной амбулаторно-поликлинической практики (по данным РЕгистра КардиоВАскулярных ЗАболеваний РЕКВАЗА). Рациональная Фар-макотерапия в Кардиологии 2014; 10(4): 366-77).

26. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-40.

27. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-41. Received / Поступила: 08.08.2014